311 related articles for article (PubMed ID: 33162547)
1. [Immune therapy and tumor angiogenesis].
Takakura N
Rinsho Ketsueki; 2020; 61(9):1440-1445. PubMed ID: 33162547
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J; Mortezaee K
Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
[TBL] [Abstract][Full Text] [Related]
3. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
4. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
5. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
[TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
Viallard C; Larrivée B
Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
[TBL] [Abstract][Full Text] [Related]
9. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
10. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
11. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
13. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
Liu Z; Wang Y; Huang Y; Kim BYS; Shan H; Wu D; Jiang W
Trends Pharmacol Sci; 2019 Sep; 40(9):613-623. PubMed ID: 31331639
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization.
Wang K; Chen Q; Liu N; Zhang J; Pan X
Drug Discov Today; 2021 Nov; 26(11):2743-2753. PubMed ID: 34332098
[TBL] [Abstract][Full Text] [Related]
16. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Li S; Zhang Q; Hong Y
Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
18. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
Hegde PS; Wallin JJ; Mancao C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
[TBL] [Abstract][Full Text] [Related]
19. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
Indraccolo S
Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
[TBL] [Abstract][Full Text] [Related]
20. Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
